Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Washington

    Search
    Washington
    Show Map
    Map View
    Washington
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      113 Clinical Trials near Washington

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Serplulimab + Chemotherapy for Small Cell Lung Cancer

      Spokane Valley, Washington
      This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Mixed SCLC, Severe Allergy, Myocardial Infarction, Others
      Must Not Be Taking:Psychotropic Drugs

      200 Participants Needed

      Serplulimab + Chemotherapy for Small Cell Lung Cancer

      Portland, Oregon
      This trial tests if adding a new drug called Serplulimab to standard treatments (chemotherapy and radiotherapy) can help patients with a specific type of lung cancer. Serplulimab aims to boost the immune system to fight cancer more effectively. Serplulimab has shown benefits when combined with chemotherapy in previous trials.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Mixed SCLC, Active Malignancies, Severe Allergy, Others

      511 Participants Needed

      Power Preferred

      SEP-363856 for Major Depressive Disorder

      Everett, Washington
      A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, PTSD, Others

      900 Participants Needed

      Active on Power

      Osavampator as an Adjunctive Treatment for Depression

      Everett, Washington
      This trial evaluates whether adding the investigational drug Osavampator (also known as NBI-1065845) to existing oral antidepressant therapy can improve depressive symptoms in patients with depression who aren’t adequately responding to their current antidepressant medication(s).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other Psychiatric Disorders, Suicide Risk, Others
      Must Be Taking:Oral Antidepressants

      200 Participants Needed

      Active on Power

      Fasedienol Nasal Spray for Social Anxiety

      Everett, Washington
      This Phase 3 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement. In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Alcohol Use, Others
      Must Not Be Taking:Psychotropics, CBD, Herbal

      236 Participants Needed

      Active on Power

      Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)

      Mill Creek, Washington
      This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Malignancies, Transplant, Infections, Others
      Must Be Taking:Biologics, Oral JAKi

      249 Participants Needed

      Active on Power

      MM120-300 for Anxiety

      Portland, Oregon
      The reason for this study is to see if the investigational study drug, called MM120, can help people with Anxiety compared to a placebo. A placebo is an inactive drug that looks like MM120 but does not contain any active ingredients.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:PTSD, Schizophrenia, Bipolar, Others
      Must Not Be Taking:Psychedelics

      198 Participants Needed

      Active on Power

      CYB003 for Depression

      Everett, Washington
      The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Suicide Risk, Others
      Must Be Taking:Antidepressants

      330 Participants Needed

      Active on Power

      ABX-002-2001 for Depression

      Bellevue, Washington
      The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.  This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening (approximately 35 days)  2. Treatment period (42 days)  3. Follow-up (2 weeks post treatment)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Epilepsy, Others
      Must Be Taking:SSRIs, SNRIs

      230 Participants Needed

      Active on Power

      Psychedelic-Assisted Therapy for Treatment Resistant Depression

      Bellevue, Washington
      This study is testing VLS-01, a treatment containing DMT that is placed in the mouth and dissolved, to see if it can quickly help people with depression who haven’t improved with other treatments. Participants will receive either 1 or 3 doses of VLS-01, with support throughout the study, to evaluate its safety and effectiveness.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorders, Substance Use, Cardiovascular, Others
      Must Be Taking:Antidepressants

      142 Participants Needed

      Active on Power

      SP-624 for Depression

      Everett, Washington
      This trial is testing the efficacy of an investigational drug, SP-624 (study drug) to see how well it might work to treat major depressive disorder.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Schizophrenia, Bipolar, Cardiovascular, Others

      456 Participants Needed

      Active on Power

      ABX-002 for Bipolar Depression

      Bellevue, Washington
      The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment shows effects on brain chemistry that may relate to anti depressive effects This is a single treatment arm, open-label, Phase 2 study of ABX-002 in 30 adults with bipolar disorder and 5 healthy volunteers. Healthy volunteer participants will receive no drug treatment and will undergo 2 imaging sessions to confirm instrument and test - retest method reliability control. For bipolar disorder participants with depression, the study will include 3 study periods: 1. Screening Period of up to 4 weeks 2. 6-week Treatment Period 3. 2-week post dose Safety Follow-up Period. For healthy volunteers, the study will include 2 study periods: 1. Screening Period of up to 3 weeks 2. Imaging Period of up to 3 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Rapid Cycler, Schizophrenia, OCD, Others
      Must Be Taking:Mood Stabilizers, Atypical Antipsychotics

      35 Participants Needed

      BI 456906 for Obesity

      Spokane, Washington
      This trial tests a medicine called survodutide, which is injected regularly to help people with obesity or overweight lose weight. It focuses on adults with a high BMI and related health issues who have tried dieting before. The goal is to see if survodutide can reduce serious heart problems and improve overall health.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Gastric Abnormalities, Others
      Must Not Be Taking:GLP-1R Agonists

      4935 Participants Needed

      BI 456906 for Diabetes and Obesity

      Renton, Washington
      This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Gastric Issues, Pancreatitis, Thyroid Cancer, Others
      Must Be Taking:Diet, Exercise

      755 Participants Needed

      ONC-392 vs Chemotherapy for Lung Cancer

      Spokane, Washington
      This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Brain Metastasis, Active Infections, Others
      Must Not Be Taking:Systemic Steroids

      600 Participants Needed

      Long-term Remibrutinib for Chronic Hives

      Seattle, Washington
      This trial tests remibrutinib, a medication for adults with chronic hives not helped by standard treatments. It aims to see if remibrutinib can reduce symptoms by blocking signals that cause hives. Remibrutinib is a highly selective, oral medication that has shown promising efficacy and safety in treating chronic spontaneous urticaria.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Bleeding Risk, Hepatic Disease, Others
      Must Not Be Taking:Anti-platelets, Anticoagulants

      696 Participants Needed

      Capivasertib + CDK4/6 Inhibitors + Fulvestrant for Breast Cancer

      Tacoma, Washington
      A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Radiotherapy, Major Surgery, Others
      Must Be Taking:CDK4/6 Inhibitors, Fulvestrant

      895 Participants Needed

      Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

      Portland, Oregon
      Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Obstructive Airway, Cardiac Disease, Others
      Must Be Taking:Pirfenidone, Nintedanib

      576 Participants Needed

      ADHD Medication + Parent Training for ADHD Families

      Seattle, Washington
      This study will compare the effectiveness of combined parental stimulant medication and behavioral parent training (BPT) versus BPT alone on child ADHD-related impairment (primary outcome), child ADHD and externalizing symptoms, time to child stimulant prescription (secondary child outcomes) and parental ADHD impairment, parental ADHD symptoms, parenting, and BPT engagement (parental outcomes/target mechanisms). This study will also assess the care delivery context and develop an implementation approach for treatment of families with a parent with ADHD and a child with elevated ADHD symptoms via telehealth in primary care sites providing pediatric care.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:3 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Bipolar, Schizophrenia, Others
      Must Be Taking:Stimulants

      240 Participants Needed

      Lenalidomide +/- Daratumumab for Multiple Myeloma

      Tacoma, Washington
      Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Smoldering Myeloma, Plasma Cell Leukemia, Amyloidosis, Others
      Must Be Taking:DVT Prophylaxis

      1100 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50
      Match to a Trial

      Simvastatin for Liver Cirrhosis

      Seattle, Washington
      This trial tests if simvastatin can prevent serious liver problems in U.S. Veterans with early-stage liver damage. Simvastatin not only lowers cholesterol but also helps protect the liver from further damage and reduces the risk of severe liver issues. Statins, including simvastatin, have been increasingly recognized for their potential benefits in treating chronic liver diseases, including cirrhosis, by reducing portal pressure and protecting against liver damage.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Statin Use, Hepatocellular Carcinoma, ASCVD, Others
      Must Not Be Taking:CYP34A4 Inhibitors

      142 Participants Needed

      Pritelivir vs Foscarnet for Resistant Herpes

      Seattle, Washington
      This trial compares two treatments for herpes infections in patients with weakened immune systems who do not respond to standard treatment. One treatment is a pill called pritelivir, and the other is a drug called foscarnet. Both aim to stop the virus from replicating and help heal sores. Foscarnet has been used to treat herpes viruses, including drug-resistant cytomegalovirus (CMV) and herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Hemodialysis, Significant Diseases, Others
      Must Not Be Taking:Acyclovir, Valacyclovir, Famciclovir

      153 Participants Needed

      Chemotherapy Combinations for Triple-Negative Breast Cancer

      Seattle, Washington
      This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Cardiac Disease, Hypertension, Others
      Must Not Be Taking:Sex Hormones, Corticosteroids

      782 Participants Needed

      Eflornithine + Sulindac for Colorectal Cancer Prevention

      Tacoma, Washington
      The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:High Cardiovascular Risk, Uncontrolled Hypertension, Gastric/duodenal Ulcer, Others
      Must Not Be Taking:Corticosteroids, NSAIDs, Anticoagulants

      354 Participants Needed

      Psilocybin for Depression

      Seattle, Washington
      The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Severe Substance Use, Others
      Must Be Taking:Antidepressants

      240 Participants Needed

      CD388 for Flu Prevention

      Renton, Washington
      The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when given as a single dose via 3 subcutaneous (SQ) injections to adult and adolescent participants who are at higher risk of developing influenza complications, and to evaluate the safety and tolerability of CD388, as compared to placebo.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Influenza, Severe CKD, Others
      Must Not Be Taking:Zanamivir, Monoclonal Antibodies

      6000 Participants Needed

      Pembrolizumab + Chemotherapy for Cervical Cancer

      Post Falls, Idaho
      This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Prior Therapy, Autoimmune, Cardiac, Others
      Must Not Be Taking:Immunotherapy, Steroids

      336 Participants Needed

      Educational Website for Colorectal Cancer

      Walla Walla, Washington
      This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that aligns with current guidelines (guideline-concordant). Surveillance care after resection of colorectal cancer is critical to detect potentially curable return of disease (recurrence), yet up to 60% of colorectal cancer survivors fail to receive surveillance. This may be due to a lack of knowledge about the purpose of surveillance care and the risks of cancer recurrence, or a lack of confidence for managing surveillance care. The CTAC intervention is an online education intervention designed to improve patients' knowledge about surveillance and their self-efficacy for managing surveillance, and to promote effective communication with supporters and supporter engagement in patients' surveillance in a way that is aligned with each patient's preferences. By increasing a patient's knowledge, self-efficacy, and satisfaction with their supporter's engagement in their care, the CTAC intervention may increase the number of patients who receive guideline-concordant surveillance care after resection of colorectal cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Stage IV Cancer, Prior Malignancy, Others

      1057 Participants Needed

      Gemcitabine + BCG for Bladder Cancer

      Post Falls, Idaho
      This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Neuroendocrine Carcinoma, Muscle-invasive Cancer, Others
      Must Be Taking:BCG

      330 Participants Needed

      Gabapentin for Pain in Head and Neck Cancer

      Post Falls, Idaho
      This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation treatment and can cause severe pain, dysphagia, and weight loss resulting in feeding tube placement, worse health-related quality of life, treatment interruptions, unplanned hospitalizations, and significant financial burden. Mucositis pain is often treated with opioid pain medications which do provide pain relief but have many known side effects not limited to mental clouding, constipation, fatigue, endocrinopathy, neurotoxicity, sleep-disordered breathing, and most distressingly persistent opioid use. Gabapentin may help relieve pain from oral mucositis caused by radiation while also reducing the need for opiate pain medications for patients receiving chemotherapy and radiation for squamous cell carcinoma of the head and neck region
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Dialysis, Transplanted Organs, Brain Metastases, Others
      Must Not Be Taking:Opioids, Mefloquine, Antipsychotics

      228 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Clinical Trials near Washington

      Top Clinical Trials near Washington, DC

      Top Clinical Trials near Fort Washington, MD

      Top Depression Clinical Trials near Washington Dc, DC

      20 Bipolar Disorder Trials near Washington, DC

      31 Schizophrenia Trials near Washington, DC

      Top Clinical Trials near Fort Washington, PA

      190 Clinical Trials near Bothell, WA

      Top Clinical Trials near Illinois

      Top Clinical Trials near Connecticut

      Top Clinical Trials near Florida

      Top Clinical Trials near Meridian, ID

      By Trial

      Community Health Worker Support for Cancer Survivorship

      Food as Medicine for Cardiometabolic Health

      Implementation Strategies for Medication-Assisted Treatment for Opioid Addiction

      Cerebral Monitoring for Cardiac Surgery Outcomes

      Genetic Results Return for Cancer Patients

      Focused Ultrasound for Tobacco Use Disorder

      Genomic Assessment for Mutation Clearance in Acute Myeloid Leukemia

      Chemotherapy and Radiation for Cutaneous Angiosarcoma

      Chemotherapy + Bevacizumab for Abdominal Cancer

      Darbe + IV Iron for Premature Infants

      Stem Cell Transplant Prep Regimen for Immune Deficiency Disorders

      Palbociclib + Chemoradiation for Head and Neck Cancer

      Related Searches

      Top Clinical Trials near Billings, MT

      Top Alzheimers-disease Clinical Trials near Lancaster, CA

      Top Clinical Trials near Arkansas

      Deep Brain Stimulation for Parkinson's Disease

      Dietary Assessment for Early Childhood Dietary Intake

      Hydraderm for Male Pattern Baldness

      Specialized Employment Program for Autism

      Reduced-Dose Chemotherapy for Breast Cancer

      Pembrolizumab for Early-Stage Non-Small Cell Lung Cancer

      Transcranial Magnetic Stimulation for Motor Skill Learning

      Digital vs. Speculum Exams for Premature Rupture of Membranes

      MR-Guided Cryoablation for Recurrent Prostate Cancer

      Frequently Asked Questions

      How much do clinical trials in Washington pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Washington work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Washington 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Washington is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Washington several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Washington?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Washington?

      Most recently, we added Pembrolizumab + Chemotherapy for Cervical Cancer, Psilocybin for Depression and Morphine or Ketamine for Pain to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards in Washington?

      The clinics in Washington currently recognized as Power Preferred are: Core Clinical Research in Everett, Washington